Inocras Raises $31M Series B-3

Inocras, based in San Diego, is a bioinformatics company that uses proprietary analytics and whole-genome data to provide actionable clinical insights for oncology. The company recently raised $31 million in an oversubscribed Series B-3 financing round, bringing its total funding to approximately $100 million.

Investors

The funding round saw participation from a variety of strategic and financial investors. Participating firms include NDS Corporation, Aimed Bio Inc., IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities, Shinhan Securities, DSC Investment, Dunamu & Partners, and InterVest.

Inocras Use of Funds

Inocras intends to use the capital to expand its U.S. commercial and operational infrastructure, aiming to bring its whole-genome sequencing and bioinformatics platform to the U.S. market following successful clinical deployments in Asia.

About Inocras

Founded to redefine precision health, Inocras develops bioinformatics platforms that integrate whole-genome data with automated interpretation. The company offers specialized solutions such as CancerVision and MRDVision to support precision oncology by analyzing complex genomic biomarkers.

Funding Details

Company Website: https://inocras.com

Company: Inocras Inc.
Raised: $31M
Round: Series B-3
Funding Date: August 3, 2026
Additional Investors: NDS Corporation, Aimed Bio Inc., IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities, Shinhan Securities, DSC Investment, Dunamu & Partners, InterVest
Company Website: https://inocras.com
Software Category: Bioinformatics
Source: https://www.businesswire.com/news/home/20260803380549/en/Inocras-Closes-%2431-Million-in-Oversubscribed-Series-B-3-Financing-to-Accelerate-U.S.-Commercial-Expansion